415 related articles for article (PubMed ID: 35331984)
1. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.
Hodkinson A; Tsimpida D; Kontopantelis E; Rutter MK; Mamas MA; Panagioti M
BMJ; 2022 Mar; 376():e067731. PubMed ID: 35331984
[TBL] [Abstract][Full Text] [Related]
2. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
3. Statins for the primary prevention of cardiovascular disease.
Taylor F; Huffman MD; Macedo AF; Moore TH; Burke M; Davey Smith G; Ward K; Ebrahim S
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004816. PubMed ID: 23440795
[TBL] [Abstract][Full Text] [Related]
4. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.
Naci H; Brugts JJ; Fleurence R; Ades AE
Eur J Prev Cardiol; 2013 Aug; 20(4):658-70. PubMed ID: 23529608
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
6. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.
Cai T; Abel L; Langford O; Monaghan G; Aronson JK; Stevens RJ; Lay-Flurrie S; Koshiaris C; McManus RJ; Hobbs FDR; Sheppard JP
BMJ; 2021 Jul; 374():n1537. PubMed ID: 34261627
[TBL] [Abstract][Full Text] [Related]
7. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.
Naci H; Brugts JJ; Fleurence R; Tsoi B; Toor H; Ades AE
Eur J Prev Cardiol; 2013 Aug; 20(4):641-57. PubMed ID: 23447425
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin for lowering lipids.
Adams SP; Alaeiilkhchi N; Tasnim S; Wright JM
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD013673. PubMed ID: 37721222
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Sadeq A; Elnour AA; Farah FH; Ramadan A; Baraka MA; Don J; Amoodi AA; Sam KG; Mazrouei NA; Alkaabi M
Curr Rev Clin Exp Pharmacol; 2023; 18(2):120-147. PubMed ID: 35642121
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
[TBL] [Abstract][Full Text] [Related]
12. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.
Kim JY; Choi J; Kim SG; Kim NH
Diabetes Metab J; 2023 Nov; 47(6):837-845. PubMed ID: 37915183
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Welty FK; Lewis SJ; Friday KE; Cain VA; Anzalone DA
J Womens Health (Larchmt); 2016 Jan; 25(1):50-6. PubMed ID: 26539650
[TBL] [Abstract][Full Text] [Related]
14. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Eur J Prev Cardiol; 2016 May; 23(7):744-7. PubMed ID: 26246463
[TBL] [Abstract][Full Text] [Related]
15. Statins for the primary prevention of cardiovascular disease.
Taylor F; Ward K; Moore TH; Burke M; Davey Smith G; Casas JP; Ebrahim S
Cochrane Database Syst Rev; 2011 Jan; (1):CD004816. PubMed ID: 21249663
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
17. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.
Naci H; Brugts J; Ades T
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):390-9. PubMed ID: 23838105
[TBL] [Abstract][Full Text] [Related]
18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
